Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
← catalyst calendarNCT06975410 · readout ≤ 314 d
Sponsored by Yuhan Corporation (industry) · 000100.KS — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
80estimated
Sites
4
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-12 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- EGFR Overexpression
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
Intervention
- Drug: YH32364
Primary outcomes
what the primary-completion date above is the date OFTreatment-emergent adverse events (TEAEs) including dose limiting toxicities (DLTs)
measured Study Day 1 to Study Day 28 (during the DLTs evaluation period)
Objective Response Rate (ORR)
measured through dose expansion part completion, approximately 1.5 year
Permalink · 000100.KS's whole pipeline · Catalyst calendar · Every registered study · What changed